Celltrion Healthcare showcase data relating to subcutaneous formulation of infliximab, Remsima® SC, UK post-Brexit drug stockpiles are at risk, Remdesivir for COVID-19 patients is ‘favourable’, and Eli Lilly and Company announce start of Phase 1 study second potential COVID-19 antibody treatment.
Interested in Star’s innovative outsourcing and resourcing solutions?
Contact Operations Director, Mark Ward, on 07872 105 540 or email email@example.com.
On the hunt for a new role, or just curious?
Visit our candidate page, submit your CV to firstname.lastname@example.org, or give our offices a ring!
At the European E-Congress of Rheumatology 2020 (The European League Against Rheumatism (EULAR) 2020 E-Congress), Celltrion Healthcare showcased three sets of data relating to a subcutaneous formulation of infliximab, Remsima® SC.
The first ever systematic benefit-risk analysis of the antiviral remdesivir for COVID-19 has found a ‘favourable’ profile overall, though safety data remains limited, researchers said.
The UK has been warned by the pharmaceutical industry that some stockpiles of medical supplies have been "used up entirely" by the virus.
Researchers have found that the Kawasaki-like syndrome reported in some children with coronavirus is actually a new inflammatory condition.
Eli Lilly and Company announced that its partner Junshi Biosciences has dosed the first healthy volunteer in a study of a potential neutralising COVID-19 antibody treatment.
While you’re here…
…and are interested in our content, why not sign up to our newsletter?
It’s just below here.